BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up – What’s Next?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares gapped up prior to trading on Tuesday . The stock had previously closed at $9.80, but opened at $10.13. BioCryst Pharmaceuticals shares last traded at $9.7990, with a volume of 3,202,925 shares.

Wall Street Analyst Weigh In

BCRX has been the subject of several research reports. Weiss Ratings upgraded BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Wednesday, March 4th. Royal Bank Of Canada dropped their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. HC Wainwright raised their target price on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, Evercore began coverage on BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price objective for the company. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $19.64.

BioCryst Pharmaceuticals Trading Down 2.4%

The stock has a fifty day moving average of $7.55 and a 200-day moving average of $7.44. The firm has a market capitalization of $2.40 billion, a price-to-earnings ratio of 7.97 and a beta of 0.73.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Thursday, February 26th. The biotechnology company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.07 by $1.05. The business had revenue of $163.28 million during the quarter, compared to the consensus estimate of $151.32 million. BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.BioCryst Pharmaceuticals’s revenue was up 209.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.13) earnings per share. As a group, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Insider Activity at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 150,000 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the completion of the transaction, the insider directly owned 400,703 shares in the company, valued at $3,666,432.45. This trade represents a 27.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 5.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Larson Financial Group LLC grew its position in BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,267 shares in the last quarter. Focus Partners Wealth acquired a new stake in BioCryst Pharmaceuticals during the 3rd quarter valued at $77,000. Farther Finance Advisors LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 326.8% in the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 8,109 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 2,115 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. acquired a new stake in shares of BioCryst Pharmaceuticals in the third quarter worth $81,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.